header logo en

 

10 facts web


Pazopanib in Combination With

Interferon Alpha 2-A, in Patients With

Advanced Renal Cell Carcinoma

 
 
 Last updated: January 26, 2017
 STATUS: Study has been completed (per ClinicalTrials.gov/NCT01513187)

WHO

is the trial for?

Patients with kidney cancer (Renal cell carcinoma, RCC) who currently meet the following criteria:

  • age 18 years or older
  • clear cell histology
  • documented locally advanced or metastatic renal cell carcinoma
  • in phase I prior systemic treatments are allowed
  • in phase II no prior systemic treatment allowed

WHAT

is the key question that this trial is attempting to answer?

This phase I/II is a trial in two stages:

  • In the first stage it will determine the optimal dose of the combination of a tyrosine-kinase inhibitor and an immune-modulating agent in the treatment of patients with advanced renal carcinoma.
  • The second stage aims to clarify the efficacy of this combination measured in terms of response rate.

WHY

patients might want to participate?

This clinical trial offers patients an opportunity to access a new therapy that may be effective for kidney cancer. This trial will further support the research in kidney cancer and potentially help other patients with kidney cancer. The trial might or might not have benefit in your individual case. For more about the importance and benefits of joining clinical trials, please click here.

WHEN

will the trial be open?

The study has been completed.

WHERE

is the trial available?

The trial will be available in 13 cancer centres in Spain.
For a complete list of trial locations, please click here:
 pdf Trial locations (220 KB)
 

STUDY

DESIGN

What does the study look like?

The trial for RCC patients is being done in two parts:
1. Part 1A aims to find the right dosage for the following Phase II.
2. Part 2 will evaluate the efficacy of the drug combinations given in 6-week cycles.

There will be only one study arm (group) for RCC patients. Which means all patients will receive the new treatment.

They will be assigned pazopanib (VotrientTM) in combination with interferon alfa 2-A.

Phase I: pazopanib is given orally once per day in different doses plus interferon alpha 2-A is administered subcutaneously every other day for up to 3 doses per week – in different doses as well.

Phase II: Once the right dosage is determined in the phase I trial, patients will be given the new treatment until disease progression, unacceptable toxicity, non-compliance or withdrawal of consent by the patient.

HOW

do I get more information?

Patient organisations supporting kidney cancer patients in your country may offer additional information about the trial, current recruitment status, and key contacts. Click here for a list of patient organisations serving kidney cancer patients. If there are no such organisations in your country, please email us for more information: This email address is being protected from spambots. You need JavaScript enabled to view it.

CONNECT

with other patients on this trial

If you want to connect with other patients considering or participating in this trial, you can find them here: List of organisations worldwide.

SHARE

your experience 

You want to share your experience on this trial?
Send us an e-mail to: This email address is being protected from spambots. You need JavaScript enabled to view it.
Note that your experience would be helpful for other patients and patient organisations.

RESULTS

of the study

No results are available at this time. Future results will be linked here.
Disclaimer: This is a patient-friendly summary of the clinical trial which has been provided for informational purposes only. Patients should consult their physician about any clinical trial opportunity.
 
Back to clinical trials overview: How can I find an IO clinical trial for my cancer?